Fidelity Fidelity SPDR Advertisement
Home > Boards > US OTC > Food - Processing and Agriculture >

Plandai Biotechnology, Inc. (PLPL)

PLPL RSS Feed
Add PLPL Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Aston Martin, UNDAUNTED, kthanks24
Search This Board:
Last Post: 9/2/2014 9:44:52 AM - Followers: 191 - Board type: Free - Posts Today: 3


www.plandaibiotech.com
 

Information Update May 20, 2014

Movie by Plandai:

http://vimeo.com/95723836


 

Plandaí and Cannabis – What is Our Role?

When Plandaí first announced its intention to produce a Phytofare™ Cannabinoid Extract, we were inundated with phone calls and emails—the majority of which wanted to know when and where they could buy some.  Since that time, we’ve read different articles and blog posts speculating that Plandaí is growing marijuana on its South Africa plantation and importing its extract to Washington under the Diego Pellicer brand name. 

With all of this misinformation out there, we felt it appropriate to “set the record straight” with respect to Plandaí and its involvement in the marijuana industry.

First, Plandaí is NOT presently producing any type of cannabis extract nor are we farming cannabis in South Africa, Washington or anywhere else.  There are many reasons for this, but primarily we recognize that cannabis cultivation and extract production is illegal—everywhere—unless you have special permission from the government.  Notwithstanding recent legislation in Washington and Colorado, growing, processing, possessing and selling marijuana in any form is still illegal on the federal level.  Plandaí has no intention of crossing this line.  Internationally, growing marijuana is illegal, especially in South Africa and other countries where we operate.

Initially, our attorneys believed we could set up a lab and begin testing in Washington.  We set this process in motion by designing the equipment and reaching out to local scientists and researchers.  We then determined that, if followed through upon, our activities could potentially violate federal laws and we immediately halted any efforts to produce an extract in the US.

With that being said, Plandaí believes that cannabis shows great medical potential.  Unfortunately, very little testing has been done in a true, double-blind, controlled human clinical environment.  Much of what we know is either anecdotal or backed by small lab-scale studies.  We have developed the science that will allow us to produce a highly bioavailable cannabinoid complex.  This new product should enable us to deliver a clinical dose of cannabinoids directly to human tissue and, theoretically, even cross the blood-brain barrier, enabling us to treat neuron disorders.  Without testing, however, this is all theoretical.   

Plandaí is actively working with several government agencies in hopes of being granted permission to commence testing our cannabinoid product.  Once this permission is received, it will take us about ninety days to set up an extraction lab and produce the first extract.  This extract will then be tested for purity and undergo a full chemical profile.  Only then will be begin animal studies to determine what, if any, medicinal benefits are present.  Favorable lab studies will eventually lead to human clinical trials but, again, only with proper government sanctioning. 

We believe that favorable clinical trials will eventually pave the way for government acceptance.  Especially for products like Plandaí’s which will have no psychoactive effects.  Once we reach that point, we will have several decisions to make: Do we produce an extract locally? Do we license the technology to a third party? Do we farm our own product or purchase from a local grower?  We cannot begin to answer these questions until we first have clinical results and then take account of the legal landscape at such future date.

The takeaway for our investors is that Plandaí remains committed to conducting ongoing research with a variety of different plants including cannabis and that this research will go forward as fast as the legal climate permits.  Until such time, we remain committed to obeying the laws—federal, state, and international—while we continue to champion for changes to those laws and establish industry standards.  We have a fiduciary responsibility to our shareholders to ensure that our company is built on a solid foundation of science, ethics, frugality, and adherence to the laws of the land.

We will continue to keep our shareholders aware of any changes to legislation and any government-approved dispensations we obtain.

 
 
 









Quarterly report December 2013
http://www.sec.gov/Archives/edgar/data/1317880/000126246313000072/plpl10q.htm
   

Security Details

 

Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.  


                                                                                                            A/S :        500 million confirmed / State of Nevada

                                                                                                            O/S :       Approx. 125.000.000
                                                                                                                                                                                                         
                                                                                                                                                                                  Free Float:        unknown
 

Incorporated in: NV,USA

Year of Inc.:  2012

 

Transfer Agent

Signature Stock Transfer, Inc.

Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093

972-612-4120

SignatureStock@aol.com



 

Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company’s Production Facility and Start of Commercial Production
August, 6, 2014
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial


SEATTLE, WA / ACCESSWIRE / August 6, 2014 / Plandaí Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company’s state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.

According to company spokesperson Louise Willemse, contractors are expected to finish all installation work at the company’s production facility on the Senteeko Tea Estate in South Africa between August 8 and Aug 15, 2014. The installation work includes all electrical, steam lines, equipment installation, and boiler system.

Engineers from the Indian contractor are scheduled to arrive on-site during the week of August 17 to complete the optimization and to initiate start-up of the facility. This process is anticipated to be complete during the first half of September 2014.

Commercial production of the Phytofare(TM) Catechin extract is then expected to commence with the first green tea crop of the season, which is entirely weather dependent but is anticipated to begin sometime in late September 2014 and continue through May of 2015. During the next winter season in South Africa, June through August 2015, the Company will begin processing Eureka lemons to produce approximately 200 kg of Phytofare(TM) Limonoid Glycoside Complex per day.

In addition to releasing the factory update, Plandaí also announced that the first two legs of the human clinical trial on the oral bioavailability of the company’s Phytofare™ Catechin Complex have been completed and results are expected to be released during the week of August 17, 2014. The third and final leg of the study will take place using Phytofare™ extract produced at the Senteeko facility and then entrapped in Pheroid® by scientists at North-West University in Potchefstroom, South Africa.

Concurrent with the third leg of the bioavailability study, Plandaí expects to commence a study testing the effects of Phytofare(TM) Catechin Complex in inducing weight loss. The study is being designed as a Phase II human clinical trial and will involve 100 patients over 90 days in a double-blind protocol.




Plandai Biotechnology Names Diego Pellicer Co-Founder and CannabisPioneer Jamen Shively as Vice President of Global Marketing

Recently Appointed Board Member Joins Management Team to Oversee Branding and Product Strategy

NEW YORK, NY, Feb 20, 2014 (Menafn - Marketwired via COMTEX) --Plandai Biotechnology, Inc. (otcqb:PLPL), a producer of highlybioavailable plant extracts for industries including health,wellness, nutraceutical, and pharmaceutical, announced today thatJamen Shively, a leading voice in the burgeoning marijuana industryand recently appointed Board Member of Plandai, has been named asVice President of Global Marketing.

As VP-Global Marketing, the company released, Mr. Shively will beresponsible for building brand awareness and marketing strategy forall of Plandai's operations including the Diego Pellicer(R) medicalcannabis line as well as the Phytofare(TM) botanical extracts such asthe Green Tea Catechin Complex and the Limonoid Glycoside Complex.

Roger Duffield, Chief Executive Officer of Plandai, commented on Mr.Shively's new position within the Company, "We're excited to bringJamen fully into the Plandai fold. He did a brilliant job buildingthe Diego Pellicer brand, and we're confident that he will build onthis experience as we launch the first of our products in the comingweeks. Our goal is to become the leading name in highly bioavailablebotanical extracts for both nutraceutical and pharmaceuticalapplications. Jamen has the vision and expertise to help further ustowards that end."

Mr. Shively stated, "I could not be more pleased to come aboardPlandai, first as a Director and now as a full-time member of themanagement team. Plandai is uniquely positioned in that it has noreal direct competition -- no one else in the market is selling highbioavailability plant extracts. Consumers are starting to demand morefrom their vitamins and supplements and asking to what extent are thebillions of dollars being spent on such products actually increasinghealth and wellness. My role with Plandai, as I see it, is to educatethe consumer that they need to demand more from their supplementswhile also telling the Plandai story. We have a unique opportunitywith Plandai's technology to fundamentally change how we addresswellness, health and prevention through natural, botanicalsolutions."

He added, "I am also extremely excited about the application ofPlandai's technologies to cannabis, which I believe willrevolutionize the application of cannabis to preventive andtherapeutic health, under the Diego Pellicer brand. This is theopportunity of a lifetime for me and for my colleagues at Plandai tochange the world by improving the health and wellness of mankindthrough 100% natural plant extracts. We are unlocking the potentialof nature's plant nutrients for humans and animals alike."

Jamen Shively, age 45, has a background in engineering and marketing,with specialties in artificial intelligence, the modeling andoptimization of complex networks, and the creation and positioning ofnew categories of products and services. Jamen co-founded DiegoPellicer Inc. in 2012 and built the brand from zero to the #1 mostrecognized brand of cannabis in the world in less than one year.Prior to founding Diego Pellicer, Jamen was a Corporate StategyManager for Microsoft from 2003 to 2009, where he focused on thecreation and development of new categories of software products andonline services. Preceding his Microsoft career he headed ShivelyInternational Inc., which built and operated both cybercafes andeducational computer centers in Mexico. Just prior to founding DiegoPellicer Inc., Jamen founded and headed the online marketplace forthe specialty food industry, Findood, winning first place in theNorthwest Entrepreneur Network's First Look Forum Competition for thetop new startup in 2010. Jamen completed his undergraduate work atU.C. Berkeley in Civil Engineering, and did graduate work at M.I.T.and U.C. Berkeley in Civil Engineering and Materials Science. He is aFellow of the National Science Foundation.

Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing

PLPL, BIOGY | February 20, 2014

NEW YORK, NY- via eTeligis (Feb 20, 2014) -  Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing.

 

As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex.

 

Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold. He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks. Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen has the vision and expertise to help further us towards that end." 

 

Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team. Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness. My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story. We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." 

 

He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts. We are unlocking the potential of nature's plant nutrients for humans and animals alike."

 

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.


Read more at http://www.stockhouse.com/news/press-releases/2014/02/20/plandai-biotechnology-names-diego-pellicer-co-founder-and-cannabis-pioneer#bRlEkKORllERl0oV.99
 

February 14, 2014 09:00 ET

Marijuana Entrepreneur Jamen Shively Goes Public With Plandai Biotechnology, Inc.

NEW YORK, NY--(Marketwired - Feb 14, 2014) - If Plandaí Biotechnology (OTCQB: PLPL) investors liked the idea of Diego Pellicer co-founder Jamen Shively working with the company from the outside, then they'll love the idea that he's now on the inside of this public biotech. Jamen Shively, a former Microsoft executive turned marijuana entrepreneur, has gone public being named to the Board of Directors at Plandaí. 

His experience at Microsoft alone makes this a great business move, but the media's attraction to Shively's confident approach to capturing 40 percent of the worldwide marijuana market makes his addition inside any public company a really big deal. Hopefully Plandaí is prepared for the media frenzy that is likely to occur when the national press that showed up en masse to his 2013 press conference, learns of Shively's appointment to the Board.

Plandaí recently completed a deal with Diego Pellicer, Inc. that allows it to market its Phytofare™ Cannabis extracts under the Diego Pellicer Gold brand, so it makes a lot of sense to Roger Duffield, CEO of Plandaí, to have Jamen Shively spearheading that branding process from inside the company. "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the Cannabis field." 

It's that bold leadership that makes Shively so attractive to the media and his "first to mind" approach will keep him in the headlines as the marijuana debate unfolds. With headlines like: "Ex-Microsoft Employee Is Going Big In The Marijuana Business," "Jamen Shively, Former Microsoft Manager, To Launch 'Premium Marijuana' Business In Washington," and "Ex-Microsoftie Jamen Shively Is Building A Marijuana Empire," Shively is clearly proving his point. 

The man some are calling the "Bill Gates of Cannabis" has the attention of the media and can likely command a microphone or writer just about any time he wants. For Plandaí and its investors, Shively's not a bad guy to have around your public company, especially in a burgeoning market.

And, this is exactly what Duffield understands as his company looks to move into production and sales of its Cannabis extracts. The CEO said, "As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months."


Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing

PLPL, BIOGY | February 20, 2014

NEW YORK, NY- via eTeligis (Feb 20, 2014) -  Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing.

 

As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex.

 

Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold. He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks. Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen has the vision and expertise to help further us towards that end." 

 

Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team. Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness. My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story. We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." 

 

He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts. We are unlocking the potential of nature's plant nutrients for humans and animals alike."

 

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.


Read more at http://www.stockhouse.com/news/press-releases/2014/02/20/plandai-biotechnology-names-diego-pellicer-co-founder-and-cannabis-pioneer#bRlEkKORllERl0oV.99

 

Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing

PLPL, BIOGY | February 20, 2014

NEW YORK, NY- via eTeligis (Feb 20, 2014) -  Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing.

 

As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex.

 

Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold. He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks. Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen has the vision and expertise to help further us towards that end." 

 

Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team. Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness. My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story. We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." 

 

He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts. We are unlocking the potential of nature's plant nutrients for humans and animals alike."

 

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.


Read more at http://www.stockhouse.com/news/press-releases/2014/02/20/plandai-biotechnology-names-diego-pellicer-co-founder-and-cannabis-pioneer#bRlEkKORllERl0oV.99

For press releases please visit: www.plandaibiotech.com/press-release.html

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 

Management Team
Roger Duffield
President, Chief Executive officer and member of the Board of Directors

Callum Baylis-Duffield
Vice-President and Global Director: Marketing
Sales

David Rzepnicki
Chief Financial Officer and member of the Board of Directors

Tim Matula
Investor Relations and member of the Board of Directors

Contact:
Corporate Headquarters
Address: 2226 Eastlake Ave E, #156
Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website:
http://www.plandaibiotech.com
Email: Info@plandaibiotech.com



LIST OF RESEARCHES, COVERAGE, ETC. :


http://www.cpreports.com/2013/05/22/ray-dirks-research-plandai-biotechnology-plpl-may-23-2013-by-ray-dirks/
............................... 
" Ray Dirks Research is projecting price targets for Plandaí Biotechnology, Inc. of $1.00 for the Short Term (6 to 9 Months) and $3.00 for the Long Term (1 to 3 Years)."


http://www.goldmanresearch.com/Search.html?ordering=&searchphrase=all&searchword=plandai
................................  "As commercialization and further testing occurs, the shares should approach the $2.00 level in 2013."

http://www.otcjournal.com
..................".....I've always had a 2013 price target on PLPL of $1.00. Based on the last 10 days, it looks like I'll be right on this one. I hope you own PLPL."

http://www.stockmarketmediagroup.com/wp-content/uploads/2013/04/Plandai-Biotechnology-Inc.-PLPL-Research-Report.pdf

 

                                                                                                                                                    PLANDAI BIOTECHNOLOGY at Africa                                                  

          
 

PostSubject
#11220  Sticky Note PLPL - MUST WATCH: Aston Martin 05/20/14 09:18:30 AM
#11731   taking my loss and never looking back. PNDJ 09/02/14 09:44:51 AM
#11730   Indeed ! No news anymore but we are Aston Martin 09/02/14 05:17:40 AM
#11729   $PLPL Do remember who is on our team: http://diegopellicer.com/?age-verified=acc0ae2344 captainscotty 09/02/14 12:11:51 AM
#11728   $PLPL They are all partying in the Mediterranean. captainscotty 09/01/14 11:57:17 PM
#11727   I'm not giving up on PLPL I still brandao 08/29/14 06:30:47 PM
#11726   Honestly said: PLPL is not worse than all Aston Martin 08/29/14 06:03:32 PM
#11725   Worst company ever to have updates and or brandao 08/29/14 12:45:17 PM
#11724   A 'bio-tick-shack' - whatever this shall be - Aston Martin 08/29/14 12:05:56 PM
#11723   $PLPL Hey CH...What is a "Bio-Zeckenbude" captainscotty 08/29/14 10:46:25 AM
#11722   Na ja, ob das mit dieser Bio-Zeckenbude war Chinaente 08/29/14 09:25:31 AM
#11721   I just hope that I will not be Aston Martin 08/28/14 03:43:18 PM
#11720   $PLPL Yes Mr Monkey... With a team like captainscotty 08/28/14 03:31:12 PM
#11719   had the pole in the Water 2 days now------------------tmonkey tmonkey 08/28/14 03:10:35 PM
#11718   $PLPL Time to bottom fish...:-} captainscotty 08/28/14 02:59:40 PM
#11717   $PLPL Market Cap 32 Mil.. @.025...:-] captainscotty 08/28/14 02:59:32 PM
#11716   $PLPL " ON SALE NOW" Nobody gets cheated....cause captainscotty 08/28/14 02:54:12 PM
#11715   These are penny stocks. I drank the cool Zipp11 08/28/14 01:03:16 PM
#11714   As I said: I will buy only Aston Martin 08/28/14 12:46:03 PM
#11713   bt ystrday and today to add to my tmonkey 08/28/14 12:33:03 PM
#11712   I am in since .16 and sold at Aston Martin 08/28/14 11:35:40 AM
#11711   If you've been in it since 2012. I Zipp11 08/28/14 11:24:35 AM
#11710   yes - and for all those $ 2.50 Aston Martin 08/28/14 10:16:22 AM
#11709   i think the selling will dry up soon tmonkey 08/28/14 03:04:56 AM
#11708   I like your thinking. Sounds like you did Zipp11 08/27/14 09:15:42 PM
#11707   This made me some nice change earlier this Zipp11 08/27/14 08:19:42 PM
#11706   After having this illusion since 2012 I am Aston Martin 08/27/14 03:57:44 PM
#11705   im looking for alot more here ---------------tmonkey tmonkey 08/27/14 03:31:53 PM
#11704   all this is what i i hope and tmonkey 08/27/14 03:20:55 PM
#11703   I buy when there is a real signal Aston Martin 08/27/14 03:18:29 PM
#11702   "....they should be selling product now..." - Aston Martin 08/27/14 03:15:09 PM
#11701   im buyin Down here----and with others soaking up tmonkey 08/27/14 02:38:27 PM
#11700   You are all to correct in that statement......this kfog 08/26/14 11:40:56 PM
#11699   I know the penny stock game and have Wonrac1 08/26/14 01:54:12 PM
#11698   Well, just on the way to become another Aston Martin 08/26/14 01:32:52 PM
#11697   Totally disgusted with both management and the stock Wonrac1 08/26/14 11:52:41 AM
#11696   With regards to numberless experiences with such kind Aston Martin 08/22/14 08:05:23 PM
#11695   Company spokesperson Louise Willemse appears to be full Wonrac1 08/22/14 07:44:11 PM
#11694   Calculated optimism is left when nothing is left. Aston Martin 08/21/14 04:32:17 AM
#11693   No lower than this price. Green days ahead, PNDJ 08/21/14 12:22:26 AM
#11692   Seriously this stock is terrible right now I brandao 08/20/14 09:40:48 PM
#11691   This stock is bleeding us dry Deehrm29 08/20/14 06:07:00 PM
#11690   kinda funny seeing the ads tommer 08/19/14 01:47:08 PM
#11689   Yes sir. Suppose to have a release EJM555 08/19/14 10:00:31 AM
#11688   holdin that .30 like a bulldog----got a feeling tmonkey 08/19/14 09:38:26 AM
#11687   Not sure if 'whinning' isn't the most understandable Aston Martin 08/19/14 03:48:15 AM
#11686   There is nothing to announce, that simple! I Aston Martin 08/13/14 11:09:06 AM
#11685   maybe this big silent period is for a tmonkey 08/13/14 09:31:27 AM
#11684   Amazing volume today - goes it would be Aston Martin 08/12/14 05:28:31 PM
#11683   tmonkey, 'overoptimism' is a very kind word for Aston Martin 08/08/14 03:36:07 PM
#11682   they were clearly overoptimistic before----maybe they get it tmonkey 08/08/14 12:14:04 PM
PostSubject